Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
MD vs AMSF vs THC vs KNTK vs HCA
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Specialty
Medical - Care Facilities
Oil & Gas Midstream
Medical - Care Facilities
MD vs AMSF vs THC vs KNTK vs HCA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Insurance - Specialty | Medical - Care Facilities | Oil & Gas Midstream | Medical - Care Facilities |
| Market Cap | $1.90B | $569M | $17.01B | $3.33B | $95.95B |
| Revenue (TTM) | $1.93B | $325M | $21.45B | $1.73B | $75.60B |
| Net Income (TTM) | $174M | $46M | $1.70B | $228M | $6.78B |
| Gross Margin | 25.5% | 47.6% | 42.8% | 24.8% | 41.5% |
| Operating Margin | 11.9% | 17.8% | 16.1% | 8.2% | 15.8% |
| Forward P/E | 10.3x | 14.4x | 10.9x | 42.4x | 14.2x |
| Total Debt | $660M | $491K | $13.17B | $3.87B | $50.20B |
| Cash & Equiv. | $375M | $62M | $2.88B | $4M | $1.04B |
MD vs AMSF vs THC vs KNTK vs HCA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Pediatrix Medical G… (MD) | 100 | 147.6 | +47.6% |
| AMERISAFE, Inc. (AMSF) | 100 | 49.4 | -50.6% |
| Tenet Healthcare Co… (THC) | 100 | 892.1 | +792.1% |
| Kinetik Holdings In… (KNTK) | 100 | 702.3 | +602.3% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MD vs AMSF vs THC vs KNTK vs HCA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MD ranks third and is worth considering specifically for momentum.
- +59.8% vs AMSF's -29.2%
AMSF has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.
- Lower volatility, beta 0.23, Low D/E 0.2%, current ratio 0.32x
- 14.3% margin vs THC's 7.9%
- Beta 0.23 vs MD's 0.73, lower leverage
THC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs HCA's 450.5%
- PEG 0.33 vs HCA's 0.67
- Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67
KNTK is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 3 yrs, beta 0.60, yield 16.5%
- Rev growth 19.0%, EPS growth 157.8%, 3Y rev CAGR 13.3%
- Beta 0.60, yield 16.5%, current ratio 0.69x
- 19.0% revenue growth vs MD's -4.9%
HCA is the clearest fit if your priority is efficiency.
- 11.3% ROA vs KNTK's 4.2%, ROIC 19.9% vs 1.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.0% revenue growth vs MD's -4.9% | |
| Value | Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67 | |
| Quality / Margins | 14.3% margin vs THC's 7.9% | |
| Stability / Safety | Beta 0.23 vs MD's 0.73, lower leverage | |
| Dividends | 16.5% yield, 3-year raise streak, vs HCA's 0.7%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +59.8% vs AMSF's -29.2% | |
| Efficiency (ROA) | 11.3% ROA vs KNTK's 4.2%, ROIC 19.9% vs 1.9% |
MD vs AMSF vs THC vs KNTK vs HCA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MD vs AMSF vs THC vs KNTK vs HCA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AMSF leads in 2 of 6 categories
THC leads 2 • MD leads 0 • KNTK leads 0 • HCA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
AMSF leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 232.8x AMSF's $325M. AMSF is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to THC's 7.9%. On growth, AMSF holds the edge at +10.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.9B | $325M | $21.5B | $1.7B | $75.6B |
| EBITDAEarnings before interest/tax | $252M | $58M | $4.3B | $534M | $15.5B |
| Net IncomeAfter-tax profit | $174M | $46M | $1.7B | $228M | $6.8B |
| Free Cash FlowCash after capex | $238M | $8M | $3.3B | $441M | $7.7B |
| Gross MarginGross profit ÷ Revenue | +25.5% | +47.6% | +42.8% | +24.8% | +41.5% |
| Operating MarginEBIT ÷ Revenue | +11.9% | +17.8% | +16.1% | +8.2% | +15.8% |
| Net MarginNet income ÷ Revenue | +9.0% | +14.3% | +7.9% | +13.2% | +9.0% |
| FCF MarginFCF ÷ Revenue | +12.3% | +2.5% | +15.6% | +25.5% | +10.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.9% | +10.3% | +2.8% | -7.5% | +6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.0% | -8.5% | +87.6% | -2.4% | +44.6% |
Valuation Metrics
THC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 11.8x trailing earnings, MD trades at a 36% valuation discount to KNTK's 18.4x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.9B | $569M | $17.0B | $3.3B | $95.9B |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $508M | $27.3B | $7.2B | $145.1B |
| Trailing P/EPrice ÷ TTM EPS | 11.82x | 12.27x | 12.53x | 18.43x | 15.12x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.26x | 14.42x | 10.94x | 42.44x | 14.19x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.38x | — | 0.72x |
| EV / EBITDAEnterprise value multiple | 8.66x | 8.53x | 6.34x | 13.14x | 9.37x |
| Price / SalesMarket cap ÷ Revenue | 1.00x | 1.80x | 0.80x | 1.89x | 1.27x |
| Price / BookPrice ÷ Book value/share | 2.26x | 2.30x | 1.97x | 1.04x | — |
| Price / FCFMarket cap ÷ FCF | 7.54x | 63.83x | 6.72x | 44.78x | 12.47x |
Profitability & Efficiency
AMSF leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KNTK delivers a 21.1% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $10 for AMSF. AMSF carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), MD scores 7/9 vs KNTK's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +20.1% | +9.7% | +19.6% | +21.1% | — |
| ROA (TTM)Return on assets | +8.1% | +5.6% | +5.7% | +4.2% | +11.3% |
| ROICReturn on invested capital | +14.8% | +21.9% | +13.2% | +1.9% | +19.9% |
| ROCEReturn on capital employed | +13.2% | +16.8% | +13.8% | +2.5% | +27.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 7 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.76x | 0.00x | 1.47x | 1.32x | — |
| Net DebtTotal debt minus cash | $285M | -$61M | $10.3B | $3.9B | $49.2B |
| Cash & Equiv.Liquid assets | $375M | $62M | $2.9B | $4M | $1.0B |
| Total DebtShort + long-term debt | $660M | $491,000 | $13.2B | $3.9B | $50.2B |
| Interest CoverageEBIT ÷ Interest expense | 20.20x | — | 4.28x | 5.98x | 5.37x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $7,143 for MD. Over the past 12 months, MD leads with a +59.8% total return vs AMSF's -29.2%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs AMSF's -9.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +7.7% | -18.3% | -2.7% | +37.4% | -8.6% |
| 1-Year ReturnPast 12 months | +59.8% | -29.2% | +27.4% | +28.0% | +19.7% |
| 3-Year ReturnCumulative with dividends | +67.0% | -24.8% | +178.5% | +93.9% | +57.4% |
| 5-Year ReturnCumulative with dividends | -28.6% | -18.9% | +190.4% | +93.1% | +109.7% |
| 10-Year ReturnCumulative with dividends | -67.1% | +31.8% | +523.4% | -33.5% | +450.5% |
| CAGR (3Y)Annualised 3-year return | +18.6% | -9.1% | +40.7% | +24.7% | +16.3% |
Risk & Volatility
Evenly matched — AMSF and KNTK each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMSF is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than MD's 0.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KNTK currently trades 94.8% from its 52-week high vs AMSF's 62.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.73x | 0.23x | 0.71x | 0.60x | 0.29x |
| 52-Week HighHighest price in past year | $24.99 | $48.54 | $247.21 | $51.11 | $556.52 |
| 52-Week LowLowest price in past year | $11.84 | $29.42 | $146.60 | $31.33 | $330.00 |
| % of 52W HighCurrent price vs 52-week peak | +91.8% | +62.4% | +78.5% | +94.8% | +77.1% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 34.2 | 52.9 | 51.3 | 30.8 |
| Avg Volume (50D)Average daily shares traded | 772K | 212K | 1.2M | 1.2M | 1000K |
Analyst Outlook
Evenly matched — KNTK and HCA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: MD as "Hold", AMSF as "Buy", THC as "Buy", KNTK as "Buy", HCA as "Buy". Consensus price targets imply 46.9% upside for AMSF (target: $45) vs -3.0% for MD (target: $22). For income investors, KNTK offers the higher dividend yield at 16.47% vs HCA's 0.69%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $22.25 | $44.50 | $268.00 | $47.57 | $527.45 |
| # AnalystsCovering analysts | 33 | 6 | 32 | 15 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | +8.4% | — | +16.5% | +0.7% |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | 3 | 5 |
| Dividend / ShareAnnual DPS | — | $2.55 | — | $7.98 | $2.94 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.6% | +2.1% | +8.4% | +5.3% | +10.5% |
AMSF leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). THC leads in 2 (Valuation Metrics, Total Returns). 2 tied.
MD vs AMSF vs THC vs KNTK vs HCA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MD or AMSF or THC or KNTK or HCA a better buy right now?
For growth investors, Kinetik Holdings Inc.
(KNTK) is the stronger pick with 19. 0% revenue growth year-over-year, versus -4. 9% for Pediatrix Medical Group, Inc. (MD). Pediatrix Medical Group, Inc. (MD) offers the better valuation at 11. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate AMERISAFE, Inc. (AMSF) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MD or AMSF or THC or KNTK or HCA?
On trailing P/E, Pediatrix Medical Group, Inc.
(MD) is the cheapest at 11. 8x versus Kinetik Holdings Inc. at 18. 4x. On forward P/E, Pediatrix Medical Group, Inc. is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — MD or AMSF or THC or KNTK or HCA?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -28. 6% for Pediatrix Medical Group, Inc. (MD). Over 10 years, the gap is even starker: THC returned +523. 4% versus MD's -67. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MD or AMSF or THC or KNTK or HCA?
By beta (market sensitivity over 5 years), AMERISAFE, Inc.
(AMSF) is the lower-risk stock at 0. 23β versus Pediatrix Medical Group, Inc. 's 0. 73β — meaning MD is approximately 214% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — MD or AMSF or THC or KNTK or HCA?
By revenue growth (latest reported year), Kinetik Holdings Inc.
(KNTK) is pulling ahead at 19. 0% versus -4. 9% for Pediatrix Medical Group, Inc. (MD). On earnings-per-share growth, the picture is similar: Pediatrix Medical Group, Inc. grew EPS 263. 0% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, KNTK leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MD or AMSF or THC or KNTK or HCA?
AMERISAFE, Inc.
(AMSF) is the more profitable company, earning 14. 9% net margin versus 6. 6% for Tenet Healthcare Corporation — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMSF leads at 18. 6% versus 9. 3% for KNTK. At the gross margin level — before operating expenses — THC leads at 82. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MD or AMSF or THC or KNTK or HCA more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pediatrix Medical Group, Inc. (MD) trades at 10. 3x forward P/E versus 42. 4x for Kinetik Holdings Inc. — 32. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMSF: 46. 9% to $44. 50.
08Which pays a better dividend — MD or AMSF or THC or KNTK or HCA?
In this comparison, KNTK (16.
5% yield), AMSF (8. 4% yield), HCA (0. 7% yield) pay a dividend. MD, THC do not pay a meaningful dividend and should not be held primarily for income.
09Is MD or AMSF or THC or KNTK or HCA better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, MD: -67. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MD and AMSF and THC and KNTK and HCA?
These companies operate in different sectors (MD (Healthcare) and AMSF (Financial Services) and THC (Healthcare) and KNTK (Energy) and HCA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MD is a small-cap deep-value stock; AMSF is a small-cap deep-value stock; THC is a mid-cap deep-value stock; KNTK is a small-cap high-growth stock; HCA is a mid-cap deep-value stock. AMSF, KNTK, HCA pay a dividend while MD, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.